Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours

Table 1 Demographics of the study population

	All, n = 174	No neoadjuvant tx	Neoadjuvant tx	P value
Male sex	85.1%	81.7	87.4	0.387
Age, median	61.5	64	58	0.043
Siewert stage				< 0.001
I	35.1%	16.9	47.6
II	51.7%	67.6	40.8
III	13.2%	15.5	11.7
cT stage				0.9
T2	7.5%	8.5	6.8
T3	74.7%	74.6	74.8
T4	17.8%	16.9	18.4
cN stage				0.02
Negative	17.2%	28.2	9.7
Positive	82.8%	72.8	90.3
Surgery				< 0.001
Oesophagectomy	54.0%	26.8	72.8
Gastrectomy	46.0%	73.2	27.2
pT stage
T0	11%	-	20.0
T1/2	26%	21.4	30.0
T3/4	63%	78.6	50.0
pN stage
N0	37%	24.3	48.8
N1	17%	18.6	15
N2	21%	20	21.2
N3	25%	37.1	15
pM stage
M0	94%	94.3	93.8
M1	6%	5.7	6.2

Data represent the entire study population (“All”), and the subgroups of patients with (“Neoadjuvant tx”) or without (“No neoadjuvant tx”) neoadjuvant pretreatment. Tx: Treatment.